Core Insights - Lamb Weston Holdings, Inc. is set to release its second-quarter earnings results on December 19, with analysts expecting earnings of 65 cents per share, a slight decrease from 66 cents per share in the same period last year [1] - The consensus estimate for quarterly revenue is $1.59 billion, down from $1.6 billion reported last year [1] Financial Performance - For the first quarter of fiscal 2026, Lamb Weston reported net sales of $1.66 billion, a slight increase from $1.65 billion a year earlier and exceeding the estimate of $1.62 billion [2] - Shares of Lamb Weston closed at $59.33, reflecting a 0.2% decline [2] Analyst Ratings - B of A Securities analyst maintained a Neutral rating and raised the price target from $60 to $66 [4] - Stifel analyst maintained a Hold rating and reduced the price target from $63 to $56 [4] - Jefferies analyst maintained a Buy rating but lowered the price target from $80 to $75 [4] - Barclays analyst maintained an Overweight rating and cut the price target from $87 to $69 [4]

Company Overview - Guerbet is a global leader in medical imaging, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging [5] - The company has been a pioneer in contrast agents for 98 years and employs 2,905 people worldwide [6] - Guerbet dedicated 9% of its revenue to Research & Development across four centers in France and the United States [6] - In 2024, Guerbet achieved €841 million in revenue [6] Appointment of François Convenant - François Convenant has been appointed as Senior Vice President of Interventional Radiology and will join the Guerbet Group's Executive Committee [1] - He joined Guerbet in September 2018 and has extensive international experience in the healthcare and medical device sector [2] - His previous roles involved management positions at leading companies, focusing on innovation and growth in surgical solutions and interventional devices [2] Interventional Radiology Insights - Interventional radiology is a rapidly expanding medical specialty that combines advanced imaging with minimally invasive therapeutic procedures [3] - This field is experiencing rapid growth due to an aging population and increasing demand for less invasive treatments [3] - Technological innovations, including AI, robotics, and precision imaging, are enhancing the safety and effectiveness of procedures [3] - The economic and clinical impact includes reduced costs related to complications and improved quality of life for patients [4] Guerbet's Mission and Offerings - Guerbet aims to meet the needs of healthcare institutions and practitioners by providing integrated and innovative solutions [4] - The company combines drugs, medical devices, services, and technologies, supported by dedicated training programs to enhance clinical practices [4]

WH Smith is being investigated by the City watchdog after the company revealed accounting failures in its US operations.The Financial Conduct Authority (FCA) said: "The investigation concerns potential breaches of UK Listing Principles and Rules and Disclosure and Transparency Rules in relation to the matters announced by WH Smith PLC on 19 November 2025." On that day WH Smith revealed that Carl Cowling, its chief executive of six years who had presided over the sale of the company's UK high street business ...

The In terms of returns, Why Global Diversification Matters More Than EverMarket cycles do not move in tandem across geographies. While Indian markets remain a compelling long-term growth story, global exposure—especially to the US—can help investors balance risk, reduce portfolio volatility, and access sectors that are either underrepresented or unavailable domestically.Investment flows into overseas equities rebounded sharply, rising from USD 152 million in August to USD 279 million in September. (Refere ...

Vision Marine Technologies Inc. (NASDAQ:VMAR) shares jumped 16.67% in after-hours trading to $0.28 on Thursday after pricing a best-efforts public offering.Check out the current price of VMAR stock here.In a best-efforts public offering, the underwriter agrees to sell as many shares as possible without guaranteeing a specific amount of proceeds.Offering DetailsThe marine technology and retail company priced 32 million units at $0.30 each, targeting gross proceeds of $9.6 million before fees, according to a ...

Core Viewpoint - BBVA has announced a share buyback program amounting to 3.96 billion euros ($4.64 billion), marking the largest buyback in the bank's history [1] Company Summary - The share buyback reflects BBVA's strong financial position and commitment to returning value to shareholders [1] - This buyback program is significant in size, indicating the bank's confidence in its future performance and capital management strategy [1]

What is going wrong for Nike. I mean, the problem here is the pace of change. And you're really seeing investors disappointed in how fast the turnaround is happening.So there are really two persistent sore points here that we saw from yesterday's results. The first being Converse. The iconic brand sales are down 30%.For a long time, the company has relied on sales of its iconic Chuck Taylor sneakers. But unfortunately, you know, consumers are just not as interested in the sneaker as they were before. The ot ...

Core Insights - Sai Life Sciences Limited released its Sustainability Report for 2024–25, focusing on "Driving climate action, deepening stakeholder trust" and aligning with GRI and SASB standards [1][2] Sustainability Strategy - The company's sustainability strategy is based on nine strategic pillars: water stewardship, climate action, circularity, biodiversity, sustainable procurement, human capital, governance and ethics, community engagement, and customer co-creation [2][3] - These pillars integrate sustainability into all operational stages, aligning with business objectives and stakeholder expectations [2] Sustainable Development Goals - Sai Life Sciences has defined Sustainable Development Goals (SDGs) to meet its sustainability commitments by March 31, 2027, with ongoing progress in greenhouse gas reduction and renewable energy usage [3][4] - The API manufacturing unit in Bidar is powered by 96% renewable energy, and the company has reduced specific water consumption across its facilities [3] Community Impact - The company exceeded its commitment to provide education and livelihood opportunities for 8,000 individuals from underprivileged communities, demonstrating significant community impact [3] Workforce Diversity - The organization has seen steady growth in diversity, with women representing 14% of the workforce [3] Long-term Vision - The 2024–25 Sustainability Report reflects the company's long-term view, emphasizing science, responsibility, and collaboration as central to its growth ambitions [4]

Meta Platforms Inc. (NASDAQ:META) is reportedly working on a new AI model, which will be focused on image and video processing, led by the company’s Chief AI Officer, Alexandr Wang.Focus on Image And Word ModelsThe new AI model, “Mango,” is being developed alongside Meta’s next large language model, which is text-based, reported The Wall Street Journal on Thursday. Wang discussed these AI models during an internal company Q&A session on Thursday, along with Chris Cox, Meta’s Chief Product Officer.The models ...

Core Viewpoint - Carnival Corporation is expected to report improved earnings and revenue for its fourth quarter, indicating a positive trend in financial performance [1][2]. Financial Performance - The company is projected to report quarterly earnings of 25 cents per share, an increase from 14 cents per share in the same period last year [1]. - The consensus estimate for quarterly revenue is $6.37 billion, compared to $5.94 billion a year earlier, reflecting a growth of approximately 7.2% [1]. Analyst Ratings and Price Targets - Carnival has exceeded analyst revenue estimates for six consecutive quarters and in nine of the last ten quarters overall, showcasing consistent performance [2]. - UBS analyst Robin Farley maintains a Buy rating and has raised the price target from $35 to $37 [3]. - Barclays analyst Brandt Montour keeps an Overweight rating but has reduced the price target from $37 to $36 [3]. - Susquehanna analyst Christopher Stathoulopoulos maintains a Positive rating and has increased the price target from $35 to $40 [3]. - Wells Fargo analyst Trey Bowers retains an Overweight rating and has raised the price target from $34 to $35 [3]. - Citigroup analyst James Hardiman maintains a Buy rating but has cut the price target from $38 to $36 [3].